Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.60 USD
+0.05 (3.23%)
Updated Jun 4, 2024 02:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Interpace Biosciences, Inc. [IDXG]
Reports for Purchase
Showing records 41 - 60 ( 63 total )
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Clinical Utility Data of BarreGEN Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Financing Completed; Revenue Growth Slated to Accelerate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Commercial Footprint Expands in Maryland; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
BarreGEN Patent To Be Issued; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
New Data Demonstrate PancraGen Improves Patient Outcomes; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
3Q18 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Thyroid Tests Now Covered by BCBS Federal Employee Health Benefit Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Revenue Guidance Exceeding $20M for 2018 Affirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
PancraGEN Expands Commercial Footprint; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Pennsylvania and New York State Both Approve ThyGeNEXT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
CIGNA Starts ThyraMIR Coverage; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
PancraGEN Gains Guideline Support and Indication Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Thyroid Test Now Covered by BCBS in Florida; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
1Q 2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Fourteen Blue Cross Blue Shield Plans On Board; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Further Improvement in Reimbursement and Commercial Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Cytopathology Services Integrated Through LabCorp; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Solid Revenue Growth in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Surgery or No Surgery? That Is the Question; Initiating at Buy and $3 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R